In our study, patients with colorectal cancer or breast cancer showed the potential for response to drugs targeting ERBB2. Drugs targeting the ERBB2/3 kinase domain can inhibit the continued activation of the ERBB2/3 pathway via NRG1 gene fusion, thereby inhibiting cancer progression. This evidence concerns the gene ERBB2 and breast cancer.